Evidence map›Paper›PMID 40568800›Full record

ArticleJournal of medicinal chemistry2025

Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.

Debanjan Kundu, Luca Franchini, Hale S Hasdemir, Elliot Lloyd, Jonathan Maturano, Katalin Rabl, Anna Nicole Denissiouk, Mark Schumacher, David Sarlah, Judith Hellman and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.The Journal of pharmacology and experimental therapeutics · 2026
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Debanjan KunduSchool of Chemistry and Biochemistry, College of Sciences, Georgia Institute of Technology, IBB, Parker H. Petit Institute for Bioengineering and Biosciences, Atlanta, Georgia 30332, United States.
Luca FranchiniDepartment of Pharmacology and Physiology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, New York 14642, United States.
Hale S HasdemirTheoretical and Computational Biophysics Group, NIH Resource for Macromolecular Modeling and Visualization, Beckman Institute for Advanced Science and Technology, Department of Biochemistry, and Center for Biophysics and Quantitative Biology, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0001-9191-6062
Elliot LloydDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California 94143, United States.
Jonathan MaturanoRoger Adams Laboratory, Department of Chemistry, Cancer Center at Illinois, University of Illinois, Urbana, Illinois 61801, United States.
Katalin RablDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California 94143, United States.
Anna Nicole DenissioukSchool of Chemistry and Biochemistry, College of Sciences, Georgia Institute of Technology, IBB, Parker H. Petit Institute for Bioengineering and Biosciences, Atlanta, Georgia 30332, United States.
Mark SchumacherDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California 94143, United States.
David SarlahDepartment of Chemistry, Rice University, Houston, Texas 77005, United States.ORCID 0000-0002-8736-8953
Judith HellmanDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California 94143, United States.
Emad TajkhorshidTheoretical and Computational Biophysics Group, NIH Resource for Macromolecular Modeling and Visualization, Beckman Institute for Advanced Science and Technology, Department of Biochemistry, and Center for Biophysics and Quantitative Biology, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0001-8434-1010
Cesare OrlandiDepartment of Pharmacology and Physiology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, New York 14642, United States.ORCID 0000-0002-4992-9350
Aditi DasSchool of Chemistry and Biochemistry, College of Sciences, Georgia Institute of Technology, IBB, Parker H. Petit Institute for Bioengineering and Biosciences, Atlanta, Georgia 30332, United States.ORCID 0000-0002-6731-6726

Funding

Resource for Macromolecular Modeling and VisualizationR24GM145965 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Emad Tajkhorshid · 2022 to 2026
$6.2M
The study of Gpr149 in nociception and the peripheral action of minor cannabinoidsR01AT010757 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HELLMAN, JUDITH, SCHUMACHER, MARK A · 2019 to 2023
$3.0M
Discovery of synthetic and endogenous ligands for orphan GPCR GPR156R01DC022104 · NIDCD · UNIVERSITY OF ROCHESTER · PI Cesare Orlandi · 2024 to 2026
$2.0M
Biochemistry of membrane proteins involved in lipid and cannabinoid metabolismR35GM152121 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI Aditi Das · 2024 to 2026
$1.1M
NCCIH NIH HHS R01 AT010757NIDCD NIH HHS R01 DC022104NIGMS NIH HHS R24 GM145965NIGMS NIH HHS R35 GM152121
6 · The paper itself

Abstract

Interest in nonpsychotropic cannabinoids like cannabinol (CBN) is increasing for pain therapy. This study delivers critical insights into CBN's metabolism and pharmacological effects, uncovering its therapeutic potential for pain reduction. Using metabolomics, we identify CBN-11-OH as the dominant metabolite, with lower levels of CBN-1'-OH and CBN-quinone. Computational simulations reveal CBN's stability at the CYP2C9 active site, driving hydroxy metabolite formation. We report the intricate biotransformation of CBN by multiple cytochrome P450 enzymes. CBN and its metabolites exhibit mild anti-inflammatory effects in microglial cells, though less potent than cannabigerol and cannabichromene. Receptor activation assays further reveal that CBN-1'-OH acts as a partial CB1 agonist, while CBN and its metabolites antagonize CB1 and CB2 receptors. Notably, CBN and CBN-11-OH elevate intracellular Ca

Indexed as

CannabinolCytochrome P-450 Enzyme SystemReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Sensory Receptor CellsAnimalsHumansMiceCannabinolCytochrome P-450 Enzyme SystemReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID40568800
PMCPMC12257535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.